Tumor tissue metabolomics informs metabolic reprogramming in IDH wild-type gliomas
Fernanda Monedeiro, Kariem Mahdy-Ali, Julia Bandres-Meriz, Adelheid Wöhrer, Elmar Zügner, Stefanie Stanzer, Christoph Magnes, Tadeja Urbanic-Purkart, Barbara Prietl, Amin El-Heliebi · FENS Forum 2024
IDH (isocitrate dehydrogenase) wild-type gliomas are associated with rapid progression and poorer prognosis compared to IDH mutant counterparts, justifying the search for novel treatment approaches based on the concept of personalized medicine. Here, we aimed to investigate how the metabolic state of gliomas may reflect in their clinical features and to gain insights into metabolic processes that may represent therapeutic vulnerabilities. For this purpose, tumor tissue samples from human glioblastoma (IDH wild-type, n=24), astrocytoma, and oligodendroglioma (both IDH mutant, n=11 and 4, respec
ePoster · Neuroscience